Table 5.
Identification of high-risk HPVs in breast cancer and benign or normal breast controls in case control studies.
| Reference | Country | Identification technique | HPV-positive breast cancers/total breast cancers | HPV-positive non cancer breast/total non-cancer breast controls | Main HPV types |
|---|---|---|---|---|---|
| Yu et al. (131) | Japan/China | PCR | 18/52 (35%) | 0/15 (0%) | 18, 33 |
| Damin et al. (132) | Brazil | PCR | 25/101(25%) | 0/41 (0%) | 16, 18 |
| Tsai et al. (133) | Taiwan | PCR | 8/62 (13%) | 2/42 (5%) | |
| Choi et al. (134) | Korea | PCR | 8/123 (7%) | 0/31 (0%) | 16, 18, 58 |
| Gumus et al. (135) | Turkey | PCR | 37/50 (74%) | 9/16 (56%) | 18, 33 |
| He et al. (136) | China | PCR | 24/40 (60%) | 1/20 (5%) | 16 |
| de Leon et al. (137) | Mexico | PCR | 15/41 (37%) | 0/43 (0%) | 16, 18 |
| Heng et al. (138) | Australia | IS PCR | 8/26 (31%) | 3/28 (11%) | 16, 18 |
| PCR | |||||
| Herrara-Goepfert et al. (139) | Mexico | PCR | 6/60 (10%) | 7/60 (12%) | 16 |
| Mou et al. (140) | China | PCR | 4/62 (6%) | 0/46 (0%) | 16, 18 |
| Chang et al. (141) | China | PCR | 0/48 (0%) | 3/30 (10%) | 6, 11 |
| Sigaroodi et al. (142) | Iran | PCR | 15/43 (35%) | 1/40 (3%) | 16, 18 |
| Frega et al. (143) | Italy | PCR | 9/31(29%) | 0/12 (0%) | 16, 18 |
| Glenn et al. (22) | Australia | In situ PCR | 25/50 (50%) | 8/40 (20%) | 16, 18 |
| PCR | |||||
| Liang et al. (144) | China | ISH | 48/224 (21%) | 6/37 (16%) | 16, 18, 33, 58 |
| Ahangar-Oskouee et al. (145) | Iran | PCR | 22/65 (34%) | 0/65 (0%) | 16 |
| Ali et al. (146) | Iraq | ISH | 60/129 (47%) | 3/41(7%) | 16, 18, 33 |
| Manzouri et al. (147) | Iran | PCR | 10/55 (18%) | 7/51 (14%) | 16 |
| Peng et al. (148) | China | PCR | 2/100 (2%) | 0/50 (0%) | 18 |
| Fu et al. (149) | China | PCR | 25/169 (15%) | 1/83 (1%) | 58 |
| ISH | |||||
| Li et al. (150) | China | PCR | 3/187 (2%) | 0/92 (0%) | 6, 16, 18 |
| Wang et al. (151) | China | ISH | 52/146 (36%) | 3/83 (4%) | 16, 18, 58 |
| Delgado-García et al. (152) | Spain | PCR | 131/251 (52%) | 48/186 (26%) | 16, 31, 39, 51, 59 |
| Salman et al. (153) | United Kingdom | PCR | 46/110 (42%) | 1/11 (2%) | 16, 31, 33, 39 |
| Naushad et al. (34) | Pakistan | PCR | 45/250 (18%) | 0/15 (0%) |
PCR, polymerase chain reaction; ISH, in situ hybridization; HPV, human papilloma virus.